Logo

Amgen Report Results of Sotorasib in P-II Study for KRAS G12C-Mutated Advanced NSCLC

Share this

Amgen Report Results of Sotorasib in P-II Study for KRAS G12C-Mutated Advanced NSCLC

Shots:

  • The P-II cohort of the CodeBreaK 100 clinical study involves assessing Sotorasib (AMG 510- 960mg- qd) in 126 patients with KRAS G12C-mutated advanced NSCLC. The findings will be presented at the IASLC 2020 WCLC
  • Results: @median follow up of 12.2 mos.- ORR (37.1%); DCR (80.6%); mDoR (10 mos.)- PFS (6.8 mos.). Median tumor shrinkage among all responders was 60% and complete responses observed
  • Sotorasib is 1st KRAS G12C Inhibitor to enter the clinic and is being studied in the broadest clinical program exploring 10 combinations with global sites spanning five continents

 ­ Ref: PRNewswire | Image: Amgen 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions